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Abstract
Background: SIV and HIV predominantly replicate in lymphoid tissue, but the study of virus specific CD8+ T cells in
intact lymphoid tissue is difficult, as traditional in situ tetramer staining requires fresh tissue.
Results: In this report, we demonstrate a novel technique using Qdot 655-conjugated peptide-MHC multimers to
directly visualize SIV specific cells in cryopreserved tissue biopsies from chronically SIVmac239 infected Rhesus
macaques. Qdot 655 multimers showed similar sensitivity and specificity to APC-conjugated tetramers by flow
cytometry analysis, but yielded ten-fold higher signal intensity when imaged by fluorescence microscopy. Using
this technique, we detected CD8+ T cells which recognize an immunodominant epitope (Gag CM9) in the spleen,
lymph nodes, ileum and colon. In all these tissues, the Gag CM9 positive cells were mainly located in the extra
follicular T cell zone. In the ileum and colon, we found Gag CM9 positive cells concentrated in Peyer’s patches and
solitary lymphoid follicles, a pattern of localization not previously described.
Conclusions: The use of Qdot multimers provide an anatomic and quantitative evaluation of SIV specific CD8+ T
cell responses in SIV pathogenesis, and may prove useful to studies of SIV specific CD8+ T cell responses elicited by
vaccines and other immunotherapies in the non-human primate model.
Background
While many reports have described the pivotal role CD8
+ T cells play in controlling SIV and HIV-1 replication,
the anatomic distribution of HIV or SIV specific CD8+
T cells and their relationship to HIV/SIV infected cells
has not been well characterized [1-8]. Flow cytometry
analyses of virus specific CD8+ T cells, identified by
MHC-peptide tetramer staining, have revealed impor-
tant insights into the immune cells’ quantity, phenotype,
and function, and the relationship between HLA type
and disease progression [9,10]. However, flow cytometry
does not allow direct visualization of the spatial distribu-
tion of virus specific CD8+ T cells in tissue. Previous
studies have demonstrated in situ staining of tetramers
in fresh, lightly fixed, or frozen tissue using a two step
enhancement methodology to visualize tetramer positive
cells [11-13]. However, this technique has proven sub-
optimal for frozen tissue, presenting such difficulties as
low signal intensity and poor cell morphology. Tetramer
staining thus requires fresh tissue that should be pro-
cessed within 24 h for optimal staining results and
therefore does not permit the use of archived tissue
samples.
We recently described a method for using Qdot 655-
conjugated peptide-MHC multimers (Qdot 655 multi-
mers) to detect HSV-2 specific cells in fresh genital skin
and mucosal tissue by in situ staining [14]. This report
describes the extension of that technique to frozen tissue
samples and demonstrates that by using Qdot 655 (com-
mercially available inherently fluorescent nanocrystals)
conjugated with the Mamu-A*01 MHC Class I allele
loaded with the SIVmac239 peptide Gag181-189CM9 (Gag
CM9), it is possible to stain and detect Gag CM9 positive
cells in cryopreserved lymphoid tissue from chronically
SIV infected Rhesus macaques (RMs). Gag CM9 is an
immunodominant cytotoxic T-lymphocyte epitope
restricted by the Mamu-A*01 allele and is well character-
ized in the non-human primate (NHP) model, both in
SIV infection and SIV vaccine models [9,15-17]
We detected Gag CM9 positive cells in spleen, lymph
nodes, ileum and colon biopsies. Interestingly, in the
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ileum and colon, the Gag CM9 positive cells were
mainly located in the inductive site of the gastrointest-
inal tract, e.g. Peyer’s patches and solitary lymphoid fol-
licles, respectively, a finding that to our knowledge has
not been previously reported. Both Peyer’s patches and
solitary lymph nodes are parts of the gut associated lym-
phoid tissue (GALT) which is a major reservoir for SIV/
HIV replication [18-23]. Thus the location of SIV/HIV
specific T cells in the GALT may suggest a role for
these cells in eliminating and controlling viral
replication.
The availability of a sensitive and specific technique for
in situ localization of virus specific CD8+ T cells in
archived samples will enable more detailed studies,
including direct quantitative and anatomic assessments
of the role vaccines and other immunotherapies can play
in altering the CD8+ T cell response in an NHP model.
Results
Gag CM9 Qdot 655 multimers bind to Gag CM9 specific
T-cells
To verify the specificity of the Gag CM9 Qdot 655 multi-
mers, we used them to stain a Gag CM9 specific T cell
clone, and examined the fluorescence by flow cytometer.
The T cells were stained with anti-CD3, anti-CD8 antibo-
dies and Gag CM9 Qdot 655 multimers, or Gag CM9
APC tetramers or Qdot 655 conjugated with the Mamu-
A*01 MHC Class I allele loaded with an irrelevant pep-
tide FLP (negative control). Analysis by flow cytometry
showed that all cells from the Gag CM9 T cell clone
were CD3+CD8+ cells (data not shown) and more than
99% of the cells bound Gag CM9 Qdot 655 multimers or
the Gag CM9 APC tetramer (Fig. 1A). Thus, similar sen-
sitivity was found by using flow analysis for Gag CM9
Qdot 655 multimers and the Gag CM9 APC tetramer.
Less than 0.13% of the cells bound the FLP Qdot 655
multimer (negative control, Fig. 1A). Similar data were
obtained with the SIV Tat28-35 SL8 (Tat SL8)-specific T
cell clone; more than 98% of cells bound the Tat SL8
Qdot 655 multimers and ≤ 0.10% of the cells bound the
FLP Qdot 655 multimer (data not shown).
To investigate if PBMCs from SIV infected Mamu-
A*01 positive RMs contained SIV specific CD8+T cells,
we stimulated the cells with Gag CM9 peptide and ana-
lyzed their ability to secrete TNF-a by intracellular cyto-
kine staining. We found that 0.14-4.31% of CD8+CD69+
T cells secreted TNF-a after Gag CM9 peptide stimula-
tion and between 0.32-3.94% of CD8+CD69+ T cells
secreted TNF-a after SEB stimulation (data not shown).
Next, we tested the ability of the Qdot 655 multimer to
detect the Gag CM9 specific cells within this heteroge-
neous population of cells: we stained PBMCs from SIV
infected RMs that were either Mamu-A*01 positive or
Mamu-A*01 negative and PBMCs from uninfected RMs
that were either Mamu-A*01 positive or Mamu-A*01
negative with Gag CM9 or FLP Qdot 655 multimers
together with anti-CD3 and anti-CD8 antibodies. Flow
analysis showed that 1.74-6.52% of CD3+CD8+ cells
from Mamu-A*01 positive RMs bound the Gag CM9
Qdot 655 multimer (Fig. 1B and Table 1), while ≤ 0.05%
CD8+ T cells from RMs that were either Mamu-A*01
negative and SIV infected, or Mamu-A*01 negative and
SIV uninfected, or Mamu-A*01 positive and SIV unin-
fected bound the Gag CM9 Qdot 655 multimer. These
percentages are similar to those previously reported
using APC tetramer staining [10,24-28]. Thus, binding
of the Gag CM9 Qdot 655 multimer is specific to CD8+
T cells from SIV infected Mamu-A*01 positive animals
and does not cross react with CD8+ T cells from SIV
infected, Mamu-A*01 negative animals.
We also evaluated cell suspensions of spleen and
lymph node from Mamu-A*01 positive, SIV infected
RMs; 8.29-11.40% and 3.82-5.17% of the CD3+CD8+ T
cells, respectively, bound the Gag CM9 Qdot 655 multi-
mer (Fig. 1B and Table 1). ≤ 0.17% CD8+T cells from
Mamu-A*01 negative, SIV infected RMs or from
Mamu-A*01 positive, SIV negative RMs bound the Gag
CM9 Qdot 655 multimer (Fig. 1B). ≤ 0.31% of the CD8+
T cells of any of the single cell suspensions described
above bound to the Qdot 655 multimer loaded with the
negative control peptide FLP, verifying that nonspecific
binding of the Qdot 655 multimer is low.
Staining pattern and staining intensity of Gag CM9 Qdot
655 multimer positive cells
Confocal microscopy revealed a punctate staining pat-
tern of individual cells stained with the Gag CM9 Qdot
655 multimers (Fig. 2), as has been previously reported
for tetramer staining [11,12]. We observed this punctate
pattern in the Gag CM9 T cell clone (data not shown),
Gag CM9 Qdot 655 multimer specific CD8+ T cells
from lymph node single cell suspensions (Fig. 2A), and
Gag CM9 Qdot 655 multimer specific CD8+ T cells in
colon tissue biopsies (Fig. 2C and 2D). Similar staining
patterns were found using the Gag CM9 APC tetramer
with single cell suspensions of lymph nodes (Fig. 2B).
Detailed 3-D modeling of the staining pattern using
Volocity (Improvision) software revealed the close proxi-
mity between CD8 molecules and the T cell receptor
(Fig. 2E, G). The CD8 staining and the Gag CM9 stain-
ing pattern overlapped almost entirely (Fig. 2F, H).
Cells stained with the Gag CM9 APC tetramer needed
longer exposures than those stained with the Gag CM9
Qdot655 multimer to be visualized by fluorescence
microscopy. We performed intensity measurements of Z
plane projections of cells stained with the Gag CM9
Qdot655 multimer or the Gag CM9 APC tetramer. A
ten-fold higher mean average staining intensity was
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Figure 1 Gag CM9 Qdot 655 multimer validation. A) Flow cytometry analysis of Gag CM9 specific CD8+ T cell clones showed that > 99% of
the cells bound to the Gag CM9 Qdot 655 multimer or to the Gag CM9 APC tetramer. The multimer and the tetramer are coupled with the
same Gag CM9 monomers. ≤ 0.13% of Gag CM9 specific cells bound to the negative control FLP Qdot 655 multimer. B) Flow cytometry analysis
of PBMCs and single cell suspension of lymph nodes demonstrated that a distinct population of CD3+CD8+ cells, 1.74% in blood and 3.82% in
lymph node single cell suspension, from SIV infected Mamu-A*01 positive RM bound the Gag CM9 Qdot 655 multimer. ≤ 0.17% of CD3+CD8+
cells from Mamu-A*01 positive RM that were not SIV infected or cells from Mamu-A*01 negative RM that were either SIV infected or uninfected
bound the Gag CM9 Qdot 655 multimer. ≤ 0.31% of CD3+CD8+ cells bound the FLP Qdot 655 multimer. The gating strategy was as described in
Methods. ND; not done due to lack of material.
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found for cells stained with the Gag CM9 Qdot655 mul-
timer as compared to cells stained with the Gag CM9
APC tetramer (Fig. 3A). In tissue biopsies, we were not
able to detect any Gag CM9 positive cells using the Gag
CM9 APC tetramer for in situ staining of spleen (Fig.
3B), lymph node (data not shown), ileum (data not
shown) or colon (Fig. 3C-D) tissue sections, even when
samples were exposed for ten times longer than the
biopsies stained with Gag CM9 Qdot 655 multimer.
Percentage of Gag CM9 Qdot 655 multimer positive cells
quantified by in situ staining
Snap frozen biopsies (spleen, lymph nodes, colon and
ileum) from chronically SIV infected Mamu-A*01 posi-
tive RMs were stained with Gag CM9 Qdot 655 multi-
mers followed by addition of anti-CD8 antibody. CD8
staining was not performed in tandem with Qdot or tet-
ramer staining, as some anti-CD8 antibodies may inter-
fere with or enhance tetramer binding to the TCR
ligand [12,29]. Double staining with Gag CM9 Qdot 655
multimer and CD8 confirmed that Gag CM9 positive
cells were CD8+ (Fig. 4A).
Gag CM9 positive cells were detected in all of the fro-
zen tissues analyzed that were from chronically SIV
infected and Mamu-A*01 positive RMs (Fig. 4), includ-
ing those tissue sections with low SIV copy numbers
(Table 2). The percentage of Gag CM9 specific CD8+
cells in all tissues analyzed ranged from 2.43%-9.59%
(Table 3), with some variation between different lym-
phoid compartments. In the spleen (Fig. 4A and 4B),
6.80%- 9.59% of the CD8+ T cells were specific for the
Gag CM9 Qdot 655 multimers; in the submandibular
lymph node, 3.30%- 5.21%; and in mesenteric lymph
nodes (Fig. 4C), 3.26%- 6.51%. In the ileum (Fig. 4D),
2.43%- 2.97% of the CD8+ T cells were specific for the
Gag CM9 Qdot 655 multimers; and in the colon (Fig.
4E and 4F), 3.10%- 6.74%. Thus, the highest percentage
of Gag CM9 positive cells were found in the spleen; the
colon, mesenteric-, and submandibular lymph nodes had
similar ranges of Gag CM9 positive cells; and the ileum
had the lowest percentages of Gag CM9 positive cells of
all lymphoid tissues analyzed. Because the ileum and
colon contain lamina propria with a less dense cell
population than in Peyer’s patches and solitary lymph
nodes, a higher variability in total cell number was
found in these tissues than in the other tissue types
analyzed.
We also stained the tissue biopsies with Qdot 655
multimers containing peptides corresponding to the fol-
lowing known MamuA*01 restricted SIV epitopes (for
full description see Table 4): Gag LW9, Gag QI9, Gag
LF8, Pol LV10, Pol QV9, Pol SV9, Env CL9, Env ST10,
Env TL9, Tat SL8, or VIF QA9, or FLP peptides. Few
cells (< 0.01%) were positive for Gag LW9, Gag QI9,
Gag LF8, or Pol SV9 in the spleen and no positive cells
were detected for Pol LV10, Pol QV9, Env CL9, Env
ST10, Env TL9, Tat SL8, or VIF QA9, consistent with
previous reports that the Gag CM9 response is domi-
nant in chronically SIV infected Mamu-A*01 positive
RMs [16,17]. To confirm specificity of our Qdot 655
multimer staining, we used the same Qdot 655 conju-
gated with the Mamu-A*01 MHC Class I allele but
loaded with an irrelevant peptide (FLP) as a negative
control. No staining was seen with the FLP Qdot 655
multimer (Fig. 4B-F, third column). Cryopreserved
spleen, mesenteric lymph nodes, ileum and colon tissues
biopsies were obtained from non SIV infected Mamu-
A*01 negative RM and used as further negative controls.
They were stained with the Gag CM9 Qdot 655 multi-
mer (Fig. 4B-E, right column) and with the FLP Qdot
655 multimer (data not shown); no positive cells were
detected. We found that the intraepithelial cells in the
ileum and in the colon showed higher autoflorescence
than cells in Peyer’s patches, solitary lymphoid follicles,
lymphoid follicles and spleen; and hence careful analysis
of low frequency cells, particularly in the intraepithelial
Table 1 Percentage of Gag CM9 positive cells quantified by flow cytometry analysis of single cell suspension.










% Gag CM9 of CD3
+CD8+cells
RM 1 Spleen 100 000 57 909 14 254 24.60% 1 273 8.93%
RM 2 Spleen 100 000 63 112 13 287 21.10% 1 101 8.29%
RM 3 Spleen 100 000 71 298 21 147 29.70% 2 416 11.40%
RM 1 Mesenteric LN 50 000 42 766 10 116 24.00% 509 5.03%
RM 2 Mesenteric LN 100 000 65 733 15 179 23.10% 580 3.82%
RM 3 Mesenteric LN 100 000 40 436 13 546 33.50% 701 5.17%
RM 1 PBMC 65 793 29 501 6 712 22.80% 438 6.52%
RM 2 PBMC 100 000 45 200 14 287 31.60% 249 1.74%
RM 3 PBMC 100 000 69 346 21 362 30.80% 776 3.63%
The total cell count, live lymphocyte cell count, CD3+CD8+ cell counts, percentage of CD3+CD8+ cells in the live lymphocyte population, Gag CM9+ cell counts
and percentage of Gag CM9+ cell in the CD3+CD8+ population was calculated by essaying flow staining on single cell suspension of spleen, mesenteric lymph
nodes and PBMCs. Cells were gated on live CD3+CD8+ cells. LN; lymph node
Tjernlund et al. Retrovirology 2010, 7:12
http://www.retrovirology.com/content/7/1/12
Page 4 of 14
Figure 2 Staining Patterns of Gag CM9. A) Fluorescence image of a lymphocyte from an SIV infected Mamu-A*01 positive RM stained with
Gag CM9 Qdot 655 multimer (red) and CD8 (green). B) Fluorescence image of a lymphocyte from an SIV infected Mamu-A*01 positive RM
stained with Gag CM9 APC Tetramer (red) and CD8 (green). C) Confocal fluorescence image of a colon tissue section from an SIV infected
Mamu-A*01 positive RM stained with Gag CM9 Qdot 655 multimer (Red), CD8 (green) and Dapi (blue). Scale bar = 10 μm. D) A magnified view
of the region indicated in panel C. Cells stained with Qdot 655 multimer or APC tetramer show a punctate Gag CM9 staining pattern. All images
were acquired with a 100×/1.4 oil immersion objective and further deconvolved. E-H) Volocity (Improvision) software was used to generate a
surface model of the CD8+Gag CM9+ cells shown in panel A (E, F) and panel D (G,H). E, G: CD8 (green), Gag CM9 Qdot 655 multimer (red); F,
H: overlap (yellow) of CD8 and Gag CM9 Qdot 655 multimer staining.
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Figure 3 Intensity comparison between Gag CM9 Qdot 655 multimer and Gag CM9 APC-tetramer. A) Single cell suspension cells of a
lymph node from an SIV infected Mamu-A*01 positive RM were stained with Gag CM9 Qdot 655 multimer or with Gag CM9 APC tetramer and
the staining intensity was measured. Z stack average intensity projections for six cells was used and the mean average intensity was calculated
by using Image J Software. A ten-fold higher mean average intensity was found for Gag CM9 Qdot 655 multimer as compared to the Gag CM9
APC tetramer, even though the same monomers are used in each case. B-D) Fluorescence images of tissue sections from an SIV infected Mamu-
A*01 positive RM stained with CD8 in green, Gag CM9 Qdot 655 multimer in red (left column) or Gag CM9 APC Tetramer in red (right column)
and dapi in blue. B) Images of spleen sections stained with Gag CM9 Qdot 655 multimer demonstrated abundant Gag CM9 specific cells (left
column) whereas the consecutive section stained with Gag CM9 APC Tetramer showed no Gag CM9 positive cells (right column). C) Gag CM9
positive cells were detected in a solitary lymphoid follicle within the colon section (right column) when Gag CM9 Qdot 655 multimer was used,
whereas when the consecutive slide was stained with Gag CM9 APC Tetramer no Gag CM9 positive cells could be detected (left column). D)
Gag CM9 positive cells were detected both in the lamina propria and in a small solitary lymph node in the colon (right column) when stained
with Gag CM9 Qdot 655 multimer but when the consecutive slide was stained with Gag CM9 APC tetramer no Gag CM9 positive cells were
detected (left column). Images were collected with a 20×/0.75 objective. Scale bar = 50 μm.
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Figure 4 In situ staining of CD8+Gag CM9+ cells in frozen tissue. A) Fluorescence images of a spleen tissue section from an SIV infected
Mamu-A*01 positive RM stained with CD8 (green), Gag CM9 or FLP Qdot 655 multimer (red), and DAPI (blue) demonstrating that the Gag CM9
positive cells are CD8+. Fluorescence images of B) spleen sections, C) mesenteric lymph node sections, D) ileum sections with peyer’s patch, E)
solitary lymph node in colon and F) images of lamina propria in colon tissue from SIV infected Mamu-A*01 positive RM. Left-most column,
second column, and right most column show Gag CM9 Qdot 655 multimer (red). The second column is a magnification of the left column
images. Third column; FLP Qdot 655 multimer (red). Right-most column, similar sections from a non-infected Mamu-A*01 negative RM. Images
were collected with a 20×/0.75 objective. Scale bar = 50 μm.
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region, is of importance to account for this background
fluorescence.
Spatial distribution of Gag CM9 positive cells in lymphoid
tissue
Gag CM9 positive cells were abundant and widely dis-
persed throughout the T cell zone in all the tissues
analyzed (Fig. 4). The cells showed a clustered staining
pattern (Fig. 4 and 5D), indicating possible clonal expan-
sion. In the ileum and colon the Gag CM9 positive cells
were mainly located in Peyer’s patches and solitary
lymph nodes, respectively (Fig. 4D and 4E), with few
Gag CM9 positive cells dispersed in the lamina propria
(Fig. 4F).
Table 2 SIV DNA and RNA quantification.
ID No Specimen SIV RNA copy eq/mL SIV DNA copies/10,000 cells SIV RNA copies/250 ng total RNA
RM 1 Plasma 50
RM 2 Plasma 3.3 × 106
RM 3 Plasma < 30
RM 1 Spleen 0 0
RM 2 Spleen 142 15986
RM 3 Spleen 0 0
RM 1 Submandibular LN 9 120
RM 2 Submandibular LN 391 29155
RM 3 Submandibular LN 19 28
RM 1 Mesenteric LN 10 7
RM 2 Mesenteric LN 283 9736
RM 3 Mesenteric LN 18 324
RM 1 Ileum ND ND
RM 2 Ileum 14 74
RM 3 Ileum 0 0
RM 1 Colon 0 0
RM 2 Colon 48 18755
RM 3 Colon 0 0
Plasma SIV RNA was assessed using a real-time RT-PCR assay and SIV RNA and DNA from lymphoid tissue biopsies were assayed by RT-PCR and PCR. Biopsy RNA
and DNA were amplified with the Rhesus Monkey GAPDH kit (Applied Biosystems Inc) to confirm the nucleic acids were amplifiable (data not shown). LN; lymph
node and ND; not done due to lack of material.
Table 3 Percentage of Gag CM9 positive cells quantified by imaging analysis of in situ stained lymphoid tissue
sections.
ID No Specimen Total cells/mm2 CD8+ cells/mm2 Gag CM9+ cells/mm2 % Gag CM9 of CD8+ cells
RM 1 Spleen 16 678 (± 2 032) 2 399 (± 386) 164 (± 39) 6.80 (± 0.6)
RM 2 Spleen 20 789 (± 3 552) 2 048 (± 627) 198 (± 70) 9.59 (± 2.0)
RM 3 Spleen 20 276(± 3 877) 2 694 (± 494) 206 (± 49) 7.78 (± 2.0)
RM 1 Submandibular LN 31 340 (± 4 076) 3 333 (± 511) 170 (± 11) 5.21 (± 1.1)
RM 2 Submandibular LN 20 789 (± 3 552) 4 885 (± 1 134) 255 (± 78) 5.16 (± 0.6)
RM 3 Submandibular LN 18 754 (± 3 317) 3 684 (± 232) 122 (± 22) 3.31 (± 0.5)
RM 1 Mesenteric LN 23 330 (± 3 458) 6 876 (± 1 225) 262 (± 26) 3.91 (± 1.0)
RM 2 Mesenteric LN 17 975 (± 2 866) 2 969 (± 685) 183 (± 48) 6.51 (± 2.8)
RM 3 Mesenteric LN 21 588(± 3 470) 6 476 (± 1 163) 200 (± 42) 3.26 (± 1.4)
RM 1 Ileum ND ND ND ND
RM 2 Ileum 6 812 (± 2 603) 701 (± 7) 21 (± 3) 2.97 (± 0.4)
RM 3 Ileum 6 793 (± 1 246) 629 (± 206) 15 (± 5) 2.43 (± 0.3)
RM 1 Colon 10 049 (± 4 193) 1 145 (± 135) 77 (± 16) 6.74 (± 0.9)
RM 2 Colon 11 814 (± 5 130) 2 287 (± 1 424) 76 (± 52) 3.10 (± 0.5)
RM 3 Colon 11 126 (± 4 207) 888 (± 160) 42 (± 9) 4.80 (± 0.9
The average total cell number/mm2, CD8+ cells/mm2, Gag CM9+ cells/mm2 and percentage of Gag CM9 Qdot 655 multimer positive cells in the CD8+ cell
population was calculated by using the image J particle counting program. The standard deviation is shown in brackets. Staining was performed at least three
times for each specimen and a total tissue area of 4.6 × 106 μm2 was counted for each specimen. LN; lymph node and ND; not done due to lack of material.
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We next stained for CD20 to localize the lymphoid
follicles, which harbor HIV infected CD4 cells, and folli-
cular dendritic cells, which contain infectious virus par-
ticles [21,30,31]. Co-staining of CD20 and Gag CM9
Qdot 655 multimer revealed that the majority of the
Gag CM9 positive cells in spleen, lymph node, ileum
and colon were excluded from the lymphoid follicles
(Fig. 5). However, some Gag CM9 positive cells were
seen in the junction between the follicle and the extra
follicular area, and in the extra follicular area (Fig. 5D
and 5E), indicating that some of these cells are able to
enter the B cell follicle and therefore have the potential
to come in close proximity with infected cells or cells
carrying SIV particles.
Discussion
We have developed a method to allow direct visualiza-
tion of virus specific cells in frozen tissue. The use of
SIV specific APC tetramers for in situ staining tradition-
ally requires a two-step enhancement methodology and
the use of fresh tissue, as staining in frozen tissue results
in low signal to noise ratio [11-13]. In this paper, we
report technical improvements in staining frozen tissues
using commercially available Qdots (nanocrystals).
Qdots have an intrinsic brightness and are constructed
to have seven to eight streptavidin molecules covalently
attached to each Qdot particle and thus are able to bind
32 peptide-MHC monomers under saturated conditions.
The enhanced binding and brightness are the likely
explanation for our ability to detect virus specific cells
even in frozen tissue. Imaging analysis of the Gag CM9
Qdot 655 multimer demonstrated a tenfold higher mean
staining intensity than the Gag CM9 APC tetramer,
even though similar sensitivity and specificity was found
for the two different compounds during flow cytometry
analysis. Furthermore, the frequency of the Gag CM9
Qdot 655 multimer positive cells that were detected by
in situ staining in blood, spleen, and lymph nodes was
similar to that detected by flow cytometry analysis.
Thus, the Qdot 655 multimer, when used with our opti-
mized protocol on cryopreserved tissue, allows a more
detailed in situ analysis of Gag CM9 specific CD8+ T
cells, and provides the technology for monitoring T cell
responses during SIV and other viral infections.
Our in situ study demonstrates detection of Gag CM9
positive cells in frozen lymphoid tissue (spleen, lymph
nodes and gastrointestinal tract) analyzed from chroni-
cally SIVmac239 infected Mamu-A*01 positive RMs.
The Gag CM9 positive cells were abundant, ranging
from 2.43%- 9.59% of all CD8+ cells, confirming reports
using flow cytometry or in situ staining of fresh tissues
using tetramers [10,24-28]. We also looked for CD8+ T
cells recognizing other Mamu-A*01 restricted epitopes.
Specifically, we did not detect any Tat SL8 (an epitope
that is immundominant in early SIV infection) specific
CD8+ T cells in our tissue sections, which is most likely
due to the fact that these biopsies are taken from
chronically infected rhesus macaques (77-85 days post-
SIV infection), and the Tat SL8 response usually escapes
during the acute infection phase [17]. Furthermore, no
subdominant Mamu-A*01 restricted SIV CD8+ T cells
were detected, confirming that the Gag CM9 response is
dominant in chronically SIV infected Mamu-A*01 posi-
tive RMs [17].
Among the tissue types analyzed, the highest propor-
tion of Gag CM9 cells was detected in the spleen, con-
sistent with previous findings [24,28]. Some studies have
found HIV and SIV specific cells to be more abundant
in lymphoid tissue and in the female reproductive tract
than in peripheral blood, while others have shown no
such differences [24-28,32,33]. In this study we found
some variability between the different lymphoid com-
partments. Although our current study did not analyze
the Gag CM9 response in tissue from the female repro-
ductive tract, we did see abundant Gag CM9 positive
cells in the colon. Since the female reproductive tract
and the colon are the port of entry for sexual transmis-
sion of HIV/SIV it is most likely important to have
HIV- or SIV- specific CD8+ T cells in these locations to
have the potential to control the infection at its initial
site.
In two of the three RMs, a similar percentage of Gag
CM9 positive cells was found in PBMCs as in lymphoid
tissue, while the third RM had a lower percentage of
Gag CM9 positive cells in PBMCs as compared to lym-
phoid tissue. We found no correlation between viral
load and the number of Gag CM9 positive cells/mm2 or
the percentage of Gag CM9 positive cells in the biopsies
analyzed; however, this may be due to the small sample
size of animals.
We found Gag CM9 positive cells widely dispersed
throughout the T cell zone in all the lymphoid tissues
Table 4 Nomenclature of Mamu-A*01-restricted epitopes.
Protein Amino acid positions Sequence Short name
SIV Gag 149-157 LSPRTLNAW Gag LW9
SIV Gag 181-189 CTPYDINQM Gag CM9
SIV Gag 245-262 QNPIPVGNI Gag QI9
SIV Gag 372-379 LAPVPIPF Gag LF8
SIV Pol 147-156 LGPHYTPKIV Pol LV10
SIV Pol 592-600 QVPKFHLPV Pol QV9
SIV Pol 625-633 STPPLVRLV Pol SV9
SIV Env 233-241 CAPPGYALL Env CL9
SIV Env 620-628 TVPWPNASL Env TL9
SIV Env 726-735 SSPPSYFQQT Env ST10
SIV Tat 28-35 STPESANL Tat SL8
SIV Vif 144-152 QVPSLQYLA Vif QA9
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analyzed. Of interest, we detected clusters of Gag
CM9 cells that may be indicative of recent clonal
expansion of these cells. To our knowledge, we are
the first to show accumulation of Gag CM9 positive
cells in Peyer’s patch and in solitary lymphoid follicles
in ileum and colon, respectively. We also detected
Gag CM9 positive cells in the lamina propria (effector
site), but to a smaller extent than in the Peyer’s Patch
and in solitary lymph nodes. Both of these anatomical
sites are a part of the GALT, which is considered to
comprise most of the secondary lymphoid organ sys-
tem and harbors the largest number of recently acti-
vated memory CD4+ T cells [18,20]. The GALT is
one of the largest reservoirs for SIV/HIV replication
[19-23], and CD4+ T cells are massively depleted
there during early infection [18,20,23,34]. It is there-
fore crucial that virus specific cells are present in
these sites to mount a successful immune response
against the virus.
CD20 staining was used to visualize the follicular area
of the lymphoid tissue. It has been reported that HIV
infected CD4+ cells and follicular dendritic cells harbor-
ing infectious virus particles persist in lymphoid follicles
[21,30,31]. While the majority of the Gag CM9 positive
cells were detected in the extra follicular area, some
were observed in the border between the follicle and the
extra follicular area or in the follicular area, confirming
findings from previous studies of HIV infected indivi-
duals and SIV infected monkeys [30,35]. Hong et al.
recently showed that in SIV infected RMs a small num-
ber of the Gag CM9 tetramer positive cells that were
located near or within a lymphoid follicle had a CD8low
profile, and hypothesized that the CD8low profile was
due to either T cell receptor signaling or low levels of
IL-7 in the B cell follicle [35]. Another study showed
that a subset of CD8+ T cells from uninfected humans
home to the lymphoid follicles in a CXCR5-dependent
manner, and that the cells in this location have
Figure 5 Gag CM9 T cells are located in the extra follicular area of lymphoid tissue. Fluorescence images showing sections from an SIV
infected Mamu-A*01 positive RM. A-C) Images of a solitary lymphoid follicle in a colon section. A) Gag CM9 positive cells are located in the
extra follicular region. Gag CM9 Qdot 655 multimer (red), CD20 (green). B) No CD8+ cells were located in the extra follicular region. CD8 (red),
CD20 (green). C) All CM9 positive cells were CD8+. Gag CM9 Qdot 655 multimer (red), CD8 (green). D) Image of a mesenteric lymph node
section showing that the majority of the Gag CM9 positive cells are located in the extra follicular region, but some are in the junction of the
extra follicular and follicular area. Gag CM9 Qdot 655 multimer (red), CD20 (green) E) A magnified view of the region indicated in panel D
showing the Gag CM9 positive cells the junction of the extra follicular and follicular area. All sections were stained with DAPI (blue). Images were
collected with a 20×/0.75 objective. Scale bar = 50 μm.
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characteristics of a non-cytolytic effector memory phe-
notype [36]. Together with these previous observations,
our findings suggest that some CD8+ T cells are able to
enter the lymphoid follicle. It would be of interest to
further explore the role of these virus specific CD8+cells
located near or within the B cell follicle, to understand
both the immunological interactions between the differ-
ent cells (CD8+ T cells, CD4+ T cells, B cells and follicu-
lar dentritic cells) within this compartment and the CD8
+ T cells’ role in controlling SIV replication. The Qdot
655 multimer may prove useful in undertaking a
detailed in situ analysis of the CD8+ T cell responses in
SIV infection.
Conclusion
In this study we demonstrate that by using the Gag
CM9 Qdot655 multimer instead of Gag CM9 APC tet-
ramers it is possible to directly visualize virus specific
CD8+ T cells in cryopreserved lymphoid tissue biopsies.
Qdot 655 multimers were found to have similar sensitiv-
ity and specificity as APC-conjugated tetramers by flow
cytometry analysis, but yielded ten-fold higher signal
intensity when imaged by fluorescence microscopy.
Using this technique, we detected Gag CM9 specific
CD8+ T cells in spleen, lymph nodes, ileum and colon.
In the ileum and colon, we found Gag CM9 positive
cells concentrated in Peyer’s patches and solitary lym-
phoid follicles; a pattern of localization not previously
described. The availability of a sensitive and specific
technique for in situ localization of virus specific CD8+
T cells may prove useful in the study of the pathogen-
esis of SIV infection and the role vaccines and immu-
notherapy may play in altering the CD8+ T cell response
in the NHP models.
Methods
Animals and virus
Six purpose-bred RMs (Macaca mulatta) of Indian
genetic background were used in this study. Tissue
biopsies, single cell suspensions, and PBMCs were
obtained from three Mamu-A*01 positive RMs that
were chronically infected with SIVmac239 and from one
Mamu-A*01 negative, SIV negative RM. PBMCs were
also obtained from one Mamu-A*01 positive, SIV nega-
tive RM and one Mamu-A*01 negative RM chronically
infected with SIVmac239. SIVmac239 infections were
initiated with intravenous injection of 5 ng equivalents
of SIV p27. The RMs were housed at the Oregon and
Washington National Primate Research Centers in
accordance with standards of the Center’s Animal Care
and Use Committee and the NIH “Guide for the Care
and Use of Laboratory Animals” [37]. Animal experi-
ments at both institutions were approved by the
National Primate Research Center’s Animal Care and
Use Committee.
Specimen collection
Submandibular and mesenteric lymph nodes, spleen,
ileum and colon biopsies were obtained at necropsy,
(77-85 days post-SIV infection). The biopsies were snap
frozen in OCT media (Sakura Finetek USA Inc. Tor-
rance, CA) and kept at -80°C until sectioning. Single-
cell suspensions of lymph node cells and splenocytes
were obtained by mechanically disaggregating the tis-
sues, which were filtered through a mesh followed by
standard Ficoll-Hypaque separation. PBMCs were iso-
lated by standard Ficoll-Hypaque centrifugation from
whole blood. The single cell suspensions were stored in
freezing medium (10% DMSO in fetal bovine serum
(FBS)) at -195°C.
Viral quantification
Plasma SIV RNA was assessed using a real-time RT-
PCR assay [38] with a threshold sensitivity of 30 SIV
Gag RNA copy equivalents per milliliter of plasma.
SIV DNA from the cryopreserved tissue biopsies was
isolated using the QIAamp DNA Mini Kit (Qiagen,
Valencia CA). SIV RNA from the cryopreserved tissue
biopsies was isolated using the RNAgents Total RNA
System (Promega, Madison WI). Both were quantified
using a Nanodrop spectrophotometer (Nanodrop Tech-
nologies Wilmington, DE). The amount of DNA assayed
per reaction was equivalent to 10,000 cells assuming 6.6
pg DNA per cell. The amount of RNA assayed was 250
ng per reaction. A SIVmac239 Gag sequence was cloned
into the pCR 2.1 TOPO vector (Invitrogen, Eugene, OR)
and RNA was made from this plasmid using the MEGA-
shortscript kit (Ambion, Applied Biosystems Inc, Foster
City, CA). The RNA was quantified using a Nanodrop
spectrophotometer (Nanodrop Technologies), and
diluted to 30,000 RNA copies/μL. This standard was
used to quantify SIV RNA in a ABI Prism 7700 machine
using the Invitrogen Ultrasensitive Kit. The two amplifi-
cation primers were SHIVKU1F (AGG CTG CAG ATT
GGG ACT TG) and SHIVKU1R (CCC TAA GTT GTC
CTT GTT GTG GA) and the probe was SHIVKU-1 (6
FAM AGC ACC CAC ACC CAG MGB). The PCR ther-
mocycler conditions were set for 50°C for 15 min for
cDNA synthesis, 95°C for 2 m for denaturation; and 42
cycles of amplification at 95°C for 15 s, and 60°C for 30
s. For the DNA assay, DNA from the 3D8 cell line [34]
was prepared using the same Qiagen kit as before and
diluted to 50,000 copies/μL. This standard was used to
quantify SIV DNA in the same thermocycler as before
using the ABI Taqgold enzyme system. The PCR ther-
mocycler conditions were 95°C for 10 min followed by
42 cycles at the same temperatures and times as above.
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Epitope-specific T cell clones
Gag CM9-specific and Tat SL8-specific CD8+ T cell
clones were produced as previously described [39].
Briefly, PBMCs were isolated from a chronically SIV-
mac239 infected Mamu-A*01 positive RM and the cells
were stimulated with irradiated autologous PBMC
pulsed with Gag CM9 or Tat SL8 peptide (SynPep
Corp., Dublin, CA) [40]. After 2 rounds of restimulation,
the Gag CM9- or Tat SL8-specific CD8+ T cell were
cloned by limiting dilution. Positive wells were tested
for antigen specificity by flow cytometry using intracel-
lular cytokine staining for IFN-g production and clonal-
ity was confirmed by staining with Gag CM9 (Beckman
Coulter, Miami, FL) or Tat SL8 (NIH AIDS Research
and Reference Reagent Program) peptide/MHC-tetra-
mers. The Gag CM9- and Tat SL8-specific CD8+ T cell
clones were immortalized by transduction with a human
telomerase reverse trancriptase/nerve growth factor
receptor (hTERT/NGFR) construct and the transduction
efficiency was determined by surface staining for NGFR
expression using anti-human NGFR-PE (clone C40-
1457; BD/PharMingen, San Diego, CA). Transduced
cells were further enriched by surface staining with anti-
human NGFR-PE followed by PE microbead selection
according to manufacturer’s recommendation (Miltenyi,
Auburn, CA).
Synthesis of Qdot 655 multimers and APC tetramers
Qdot 655-conjugated peptide-MHC multimers were
formed in vitro as previously described [14]. Briefly,
biotinylated Mamu-A*01/b2m/peptide monomers were
produced with the known Mamu-A*01-restricted epi-
topes as outlined in Table 4 [40]. A peptide
(FLPSDYFPSV (FLP)) from the core protein of Hepati-
tis B was also generated for use as a negative control.
Streptavidin-coated APC (Prozyme, San Leandro, CA)
or Qdot 655 (Invitrogen) was conjugated with a satur-
ating amount of biotinylated Mamu-A*01/b2m/peptide
monomers.
Cell surface flow cytometry staining
PBMC or single cell suspensions from spleen and lymph
nodes were resuspended, washed in PBS, and stained
with LIVE/DEAD Fixable Violet Dead Cell Stain (Invi-
trogen) for 30 min at room temperature (RT). The cells
were then washed in PBS with 2% FBS followed by incu-
bation with Gag CM9 Qdot 655 multimer or with FLP
Qdot 655 multimer for 30 min at RT. Anti-CD8-FITC
(SK1) and anti-CD3-PerCP (SP34-2) antibodies (BD
biosciences) were added and cells were incubated for an
additional 20 min at RT followed by washing in PBS
with 2% FBS. The cells were fixed for 10 min in 2% for-
maldehyde and cell surface expression was assessed
using a LSR II cytometer (LSR II; Becton Dickinson). All
FACS analyses were performed using FlowJo® software
(Treestar, Inc; OR). Single cells were selected and dead
cells excluded. CD3+CD8+ cells were then selected and
observed for Qdot 655 or APC staining.
Intracellular TNF-a staining
SIV-specific CD8+ T cell responses were measured by
flow cytometric intracellular cytokine analysis of PBMCs
as previously described [41]. Briefly, PBMC (1 × 106)
were incubated at 37°C for 1 h with co-stimulatory anti-
bodies against CD28 and CD49d (0.5 μg of each anti-
body; (BD Biosciences) and Gag CM9 peptide (2 μg
peptide/sample) to stimulate cognate SIV-specific CD8+
T cells. Staphylococcal enterotoxin B (SEB 0.2 μg/ml;
Toxin Techonology, Sarasota, FL) was used as a positive
control and co-stimulation in the absence of antigen
served as a negative-control. Cells were then treated
with 10 μg of brefeldin A (10 μg/ml; Sigma) to inhibit
protein trafficking for an additional 5 h at 37°C. Cells
were then washed with PBS plus 2% FBS followed by
surface and intracellular staining with the following con-
jugated antibodies from BD Biosciences: CD3 (SP34-2),
CD4 (L200), CD8 (SK1), CD69 (L78) and TNF-a
(6401.1111). Flowcytometric analysis was performed on
an LSR II cytometer (Becton Dickinson). The Gag CM9
and the SEB data were corrected against the negative
control.
In Situ staining
7 μm thick sections from cryopreserved biopsies were
cut using a cryostat, mounted on super frost plus slides
(Fisher Scientific, Pittsburg, PA) and washed in PBS
with 0.1% BSA. The sections were blocked in PBS con-
taining 2% BSA and 5% normal human serum for 30
min at RT, followed by incubation with Qdot 655 multi-
mers over night at +4°C. The next day the sections were
washed in PBS with 0.1% BSA and fixed in 2% formalde-
hyde for 10 min followed by a wash in PBS with 0.1%
saponin. The sections were incubated with mouse anti-
CD8 (RPA-T8) or mouse anti-CD20 (2H7) antibodies
(BD Biosciences) for 1 h at RT, then washed in PBS
with 0.1% saponin and incubated with donkey anti-
mouse IgG Alexa Fluor 488 (Invitrogen) for 30 min at
RT. The sections were washed in PBS with 0.1% saponin
followed by a wash in PBS prior to incubation with
DAPI (Fluka, Sigma-Aldrich, St Louis, MO) and a final
wash in MilliQ water. The tissue sections were mounted
in Mowiol 40-88 containing 2.5% wt/vol DABCO
(Sigma-Aldrich).
Detection and quantification of Qdot 655 conjugated
pMHC multimers
Fluorescence microscopy (Nikon Eclipse TE 2000-S;
Nikon Instruments Inc., Melville, NY) was used to
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visualize CD8+ cells and CD20+ cells as well as cells
positive for Qdot 655 or APC tetramer in the stained
tissue sections. Each biopsy was cut and stained for
CD8, or CD20 with the Qdot 655 multimers or the Gag
CM9 APC tetramer, and counterstained with DAPI. At
least three sections were prepared for each biopsy, and
five fields were analyzed for each tissue section. The
cells were enumerated in tissue fields of 641.5 × 479.3
micrometers and a total tissue area of 4.6 × 106 μm2
was analyzed per biopsy. At least 2,000 CD8+ cells for
each section of spleen and lymph nodes, 900 CD8+ cells
for each section of the colon, and 600 CD8+ cells for
each section of the ileum were counted using the parti-
cle counting algorithm of public domain imaging soft-
ware ImageJ. Total cells/mm2, CD8+ cells/mm2, Gag
CM9 positive cells/mm2 and the percentage of Gag
CM9 positive in the CD8+ cell population was
calculated.
To evaluate the staining pattern of CD8 and Gag
CM9 positive cells, high resolution three dimensional
images of the tissue sections were acquired either by
confocal microscopy on a Zeiss LSM 510 laser scanning
confocal microscope (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY), or by deconvolution microscopy on a
DeltaVision RT microscope (Applied Prescision Inc.,
Issaquah, WA). Excitation lasers, detection bands and
beam splitter set-up for the confocal microscopy were
as previously described [14]. Volocity software (Perkin
Elmer, Waltham, MA) was used for detailed 3-D model-
ing of the staining patterns. Average intensity Z plane
projections for single cell suspension cells stained with
Gag CM9 Qdot 655 multimer or Gag CM9 APC tetra-
mer were used for intensity calculation by Image J
software.
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